This from the spin out and dividend announcement :

"...To that end, Generex has initiated partnering discussions with synergistic companies to explore co-development and collaborative R&D opportunities for immunotherapeutic product development.”

https://finance.yahoo.com/news/gnbt-generex-b...02199.html